Purpose ONC201 is a small molecule selective antagonist of the G protein-coupled receptor DRD2 that is the founding member of the imipridone class of compounds. A first-in-human phase I study of ONC201 was conducted to determine its recommended phase II dose (RP2D). Experimental Design This open-label study treated 10 patients during dose escalation with histologically-confirmed advanced solid tumors. Patients received ONC201 orally once every 3 weeks, defined as one cycle, at doses from 125 to 625 mg using an accelerated titration design. An additional 18 patients were treated at the RP2D in an expansion phase to collect additional safety, pharmacokinetic (PK), and pharmacodynamic (PD) information. Results No Grade >1 drug-related adverse events occurred and the RP2D was defined as 625 mg. PK analysis revealed a Cmax of 1.5 - 7.5µg/mL (~3.9-19.4µM), mean half-life of 11.3 hours, and mean AUC of 37.7 h.ug/L. Pharmacodynamic assays demonstrated induction of caspase-cleaved keratin 18 and prolactin as serum biomarkers of apoptosis and DRD2 antagonism, respectively. No objective responses by RECIST were achieved, however, radiographic regression of several individual metastatic lesions was observed along with prolonged stable disease (> 9 cycles) in prostate and endometrial cancer patients. Conclusion ONC201 is a selective DRD2 antagonist that is well tolerated, achieves micromolar plasma concentrations, and is biologically active in advanced cancer patients when orally administered at 625 mg every 3 weeks.
- Received October 21, 2016.
- Revision received January 13, 2017.
- Accepted March 15, 2017.
- Copyright ©2017, American Association for Cancer Research.